Solid Biosciences to Participate in Notable Investor Conferences
Solid Biosciences Inc. (NASDAQ: SLDB), a pioneering firm in the field of genetic medicine, is excited to announce its engagement in several forthcoming investor conferences. This participation underscores its ongoing commitment to advancing innovative treatments for rare neuromuscular and cardiac diseases.
Upcoming Conferences
Jefferies Global Healthcare Conference
At the Jefferies Global Healthcare Conference, Solid Biosciences will have its President and CEO, Bo Cumbo, alongside Chief Medical Officer, Dr. Gabriel Brooks, lead a compelling fireside chat. This event is scheduled for a date in November, providing a platform for in-depth discussions about the company’s initiatives.
Piper Sandler Healthcare Conference
Following the Jefferies event, Mr. Cumbo and Dr. Brooks are also slated to participate in the Piper Sandler 37th Annual Healthcare Conference. Here, they will continue to share insights into Solid Biosciences’ strategic vision and advancements in gene therapy, scheduled for early December.
Live Webcast Access
Interested parties can view live webcasts of both the Jefferies and Piper Sandler fireside chats through the company’s Events page on its Investors section of the website. Archive replays will also be accessible for those wishing to catch up after the live events.
One-on-One Meetings
Institutional investors eager to engage directly with Solid Biosciences’ management during these conferences are encouraged to reach out to their respective Jefferies or Piper Sandler representatives to schedule one-on-one meetings.
About Solid Biosciences
Solid Biosciences is at the forefront of developing cutting-edge precision genetic medicines focused on rare neuromuscular and cardiac disorders. The company is advancing a robust pipeline that includes drug candidates like SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, among others. Solid’s broader aim is to integrate groundbreaking gene therapies that can transform patient care and improve the quality of life for those affected by these severe conditions.
Contact Information
Investor Relations:
Nicole Anderson
Director of Investor Relations and Corporate Communications
Solid Biosciences Inc.
Email: investors@solidbio.com
Media Inquiries:
Glenn Silver
FINN Partners
Email: glenn.silver@finnpartners.com
Frequently Asked Questions
What is the main focus of Solid Biosciences?
Solid Biosciences specializes in the development of precision genetic medicines for rare neuromuscular and cardiac diseases.
When are the upcoming investor conferences?
The investor conferences are scheduled in November and December, with specific dates announced for each event.
Who will represent Solid Biosciences at these conferences?
Bo Cumbo, President and CEO, and Dr. Gabriel Brooks, Chief Medical Officer, will represent the company.
How can investors access the live webcast?
Investors can access the live webcast through the Events page on the Solid Biosciences Investors section of their website.
What is the mission of Solid Biosciences?
Solid Biosciences aims to improve the daily lives of patients living with devastating rare diseases through innovative gene therapies.